New drug cocktails aim to stop bile duct cancer return after surgery
NCT ID NCT07640048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding immunotherapy (adebrelimab) to different chemotherapy or targeted therapy regimens can help prevent cancer recurrence in people with intrahepatic cholangiocarcinoma who have a high risk of the cancer coming back after surgery. About 90 participants will receive one of three treatment combinations and be compared to historical data. The goal is to see which approach improves survival without recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab, gemcitabine, cisplatin, apatinib, S-1
- What this could lead to
- If successful, this could identify better post-surgery treatments to delay or prevent cancer recurrence in high-risk patients.
- What could go wrong
- This is a small, early-phase real-world study without randomization, so results may not be conclusive. Side effects from chemotherapy and immunotherapy can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital (PUMCH)
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- New drug cocktail aims to outsmart untreatable bile duct cancer
- AI could spot liver cancer types and predict survival without needle biopsy
- New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
- Anti-Inflammatory drug may boost cancer therapy in bile duct cancer
- New pill targets gene flaws in hard-to-treat bile duct cancer